Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) SVP Bosch John Roderick Ten sold 1,416 shares of the firm’s stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $120.00, for a total value of $169,920.00. Following the completion of the sale, the senior vice president directly owned 22,219 shares of the company’s stock, valued at approximately $2,666,280. This represents a 5.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bosch John Roderick Ten also recently made the following trade(s):
- On Monday, September 21st, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $106.61, for a total value of $150,959.76.
- On Wednesday, September 9th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $97.54, for a total transaction of $138,116.64.
- On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total transaction of $141,700.00.
- On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total transaction of $131,582.62.
Billiontoone Stock Performance
NASDAQ:BLLN traded down $1.36 during trading hours on Monday, hitting $121.72. 343,637 shares of the company were exchanged, compared to its average volume of 551,483. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $150.44. The stock has a market capitalization of $5.74 billion and a price-to-earnings ratio of 173.89. The company’s 50 day moving average price is $108.73 and its 200-day moving average price is $98.51.
Hedge Funds Weigh In On Billiontoone
Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Billiontoone in the 2nd quarter valued at about $29,000. MCF Advisors LLC boosted its stake in shares of Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after buying an additional 344 shares during the last quarter. Thrive Wealth Management LLC acquired a new stake in Billiontoone during the second quarter worth about $240,000. Caitong International Asset Management Co. Ltd acquired a new stake in Billiontoone during the fourth quarter worth about $230,000. Finally, Jasper Ridge Partners L.P. purchased a new position in Billiontoone during the second quarter valued at approximately $615,000.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. Guggenheim initiated coverage on Billiontoone in a research note on Monday, June 29th. They set a “buy” rating and a $125.00 price target on the stock. BTIG Research reduced their price objective on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Canaccord Genuity Group assumed coverage on Billiontoone in a report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Billiontoone in a research report on Friday, September 18th. Finally, Wall Street Zen lowered shares of Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $125.88.
View Our Latest Research Report on Billiontoone
Billiontoone Company Profile
BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.
The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.
Recommended Stories
- Five stocks we like better than Billiontoone
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
